焦點科技(002315.SZ):參股公司Huize在納斯達克掛牌上市
格隆匯2月13日丨焦點科技(002315.SZ)公佈,公司參股公司Huize Holding Limited(下稱“Huize”)於2020年2月12日(美國時間)在美國納斯達克證券交易所掛牌上市,股票代碼為“HUIZ”,此次Huize公開發行新股525萬份美國存托股票,發行價10.5美元/ADS,每份ADS相當於20股普通股。
Huize掛牌上市後,公司通過BVI全資子公司Crov Global Holding Limited持有Huize約1.84億股普通股,佔其發行後總股本的17.7%(不考慮超額配售選擇權的影響)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.